Souhaitez-vous accéder aux communiqués récents ?

Advanced biomaterial device designed for use in lumpectomy surgeries Interim results from the first 25 of 94 patients at 6 months follow upConfirms REGENERA™ is safe and biocompatible as breast tissue...

Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process

Elutia Regains Compliance with Nasdaq Listing Requirements

Independent investigators from the University of Pisa presented new data at the 2026 European Congress of Radiology (ECR) Ultrasound follow-up documented predictable scaffold bioresorption and...

Elutia earns Great Place to Work® certification, highlighting a high-performance culture built on trust, innovation, and execution.

Clinical data from pivotal trial in patients undergoing lumpectomy confirm strong safety profile and growing performance benefits Primary safety endpoint met and encouraging secondary performance...

Dublin, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The "United States Breast Reconstruction Market Size and Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's...

Dublin, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The "Breast Reconstruction Market - Global Forecast 2025-2032" has been added to ResearchAndMarkets.com's offering. The breast reconstruction market is...

Leading international experts to support clinical development of BellaSeno´s pioneering resorbable breast implantsPivotal clinical trial to be initiated shortly Leipzig, Germany / Brisbane,...

Dublin, May 01, 2025 (GLOBE NEWSWIRE) -- The "Breast Reconstruction Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ...